Skip to main content

COVID-19 Topic Center

News

News
“Publications have shown the positive effect of therapeutic patient education on the course of the disease, the prevention of complications, and the autonomy and quality of patient life,” researchers wrote.
News
“Estimating the lifetime costs of managing HIV is useful for budgetary planning and to ensure HIV management is affordable for all,” the study concluded.
News
The cost burden of standard of care for patients with spinal muscular atrophy is substantial, and at current prices approved disease-modifying drugs for the condition have high cost-effectiveness ratios when delivered after symptom onset.
News
In November, the departing Trump administration unexpectedly ended the FDA program that led to a price spike for colchicine and other older drugs, saying it drove up drug costs and in some cases caused shortages. Now the FDA is considering whether and how to replace it, while advancing the Biden…
News
Patient-Reported Outcomes Measurement Information System Global Health scores had sufficient validity and reliability to assess health-related quality of life in atopic dermatitis, according to a recent study.
News
“Psoriasis prescriptions comprise a large, increasing proportion of Medicare Part D spending related to dermatology,” researchers wrote. “These increasing costs have significant implications for the health care system and affect out-of-pocket costs for patients who rely on such medications.”
News
According to study findings published online in Cancer Chemotherapy and Pharmacology, researchers identified the optimal dose of selinexor in patients with diffuse large B-cell.
News
According to a cross-sectional study, patients with non-radiographic axial spondyloarthritis at moderate risk of cardiovascular disease per the Systematic COronary Risk Evaluation (SCORE) model were reclassified as very high risk after ultrasound imaging revealed carotid plaques.
News
For the treatment of moderate-to-severe atopic dermatitis, biologics with the most robust efficacy and safety evidence are dupilumab, baricitinib, abrocitinib, and delgocitinib, according to a systematic review.
News
Many officials are concerned that Blue Shield's take over of the vaccination program will cause health care workers to waste valuable time learning new data systems and software instead of tracking down the state's most vulnerable vaccine-eligible residents.
Back to Top